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The paramyxovirus, simian virus 5, fusion (F) protein contains seven amino acids between heptad repeat B (a domain
required for a biologically active fusion protein) and the presumptive boundary of the transmembrane (TM) domain. The role
of the seven membrane proximal residues in stability and fusion promotion was examined by construction of a series of
insertion, substitution, and deletion mutants, as manipulation of this region to enable proteolytic cleavage would facilitate
production of a soluble F protein. The majority of the mutant F proteins both oligomerized and had kinetics of intracellular
transport similar to those of wild-type (wt) F protein. All mutant F proteins were expressed at the cell surface at or near the
same level as the wt F protein. However, by using both a qualitative lipid mixing assay and a quantitative content mixing assay
for membrane fusion, it was found that mutant F proteins containing insertions in the region between heptad repeat B and
the TM domain were unable to induce fusion, whereas the mutant F proteins containing substitutions in this region, together
with three of the four mutants with deletions in this region, could induce fusion. Four of the F protein mutants contained a
Factor Xa cleavage site, IEGR; however, Factor Xa treatment of cell surfaces released either none or only very small amounts
(,1% of total protein) of the soluble heterodimer F1 1 F2. As an alternative method of generating soluble F protein, a glycosyl
phosphatidylinositol (GPI) anchor was added to the F protein at three membrane-proximal positions. The highest level of
surface expression was observed when the final molecule did not contain a significant insertion of amino acids into the
membrane proximal region. Two F-GPI mutants reached the surface at approximately 20% of the levels seen with the wt F
protein, and approximately 25% of the cell surface population of these mutants could be cleaved with phosphatidylinositol
phospholipase C (PI-PLC) to yield soluble F protein. However, all the F-GPI mutants oligomerized aberrantly and failed to
promote fusion. Taken together, these data indicate that the spacing of the region immediately adjacent to the presumptive
boundary of the TM domain is extremely important for the fusogenic activity of the SV5 F protein. © 1997 Academic Press
INTRODUCTION
The paramyxovirus simian virus 5 (SV5) contains two
integral membrane glycoproteins, the hemagglutinin–
neuraminidase protein (HN) and the fusion protein (F)
(Scheid et al., 1972). The HN protein mediates attach-
ment of virions to sialic acid-containing receptor mole-
cules and also has receptor-destroying (neuraminidase)
activity, whereas the F protein functions in penetration of
virus into the host cell by mediating fusion of the virion
envelope with the cellular plasma membrane. The F
protein is synthesized as an inactive precursor F0 that is
cleaved by a host cell proteolytic enzyme in the trans-
Golgi apparatus to form the biologically active protein
consisting of the disulfide-linked chains F1 and F2 (re-
viewed in Lamb and Kolakofsky, 1996). Unlike most other
paramyxoviruses, whose F proteins are able to induce
cell–cell fusion only when coexpressed with their homo-
typic HN glycoproteins (Cattaneo and Rose, 1993; Ebata
et al., 1991; Hu et al., 1992; Morrison and Portner, 1991;
Tanabayashi et al., 1992; Wild et al., 1991), the SV5 F
protein has been demonstrated to induce cell–cell fusion
in the absence of SV5 HN expression (Bagai and Lamb,
1995b; Horvath and Lamb, 1992; Horvath et al., 1992;
Paterson et al., 1985).
There are several domains in the sequence of the
paramyxovirus F proteins which appear to be analo-
gous to well-characterized domains found in the influ-
enza hemagglutinin (HA) (reviewed in Lamb, 1993).
The N-terminus of the F1 protein contains a hydropho-
bic 20-amino-acid segment, the fusion peptide, which
is thought to play a direct role in fusion by insertion
into the target membrane. It has been shown that the
fusion peptide of SV5 F protein is sufficiently hydro-
phobic that it can act as a transmembrane anchor
domain to convert a formerly soluble protein to a
membrane-bound form (Paterson and Lamb, 1987). In
addition, the fusion peptide from the F protein of Sen-
dai virus has been shown by using photoactive lipid
probes to interact directly with the target cell mem-
brane (Asano and Asano, 1985; Novick and Hoekstra,
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1988). Furthermore, mutant F proteins containing gly-
cine-to-alanine substitutions in the fusion peptide
have been shown to exhibit a great increase in fusion
kinetics (Bagai and Lamb, 1997) and an increase in the
extent of syncytium formation (Horvath and Lamb,
1992; Ward et al., 1995). Heptad repeat regions flank
both the fusion peptide and the putative TM domain,
and by analogy to influenza virus HA, they are hypoth-
esized to form important structural elements in the F
protein. Mutations in either of these two heptad repeat
regions in Newcastle disease virus (Reitter et al., 1995;
Sergel-German et al., 1994) and measles virus (Buck-
land et al., 1992) have been shown to block fusion.
Finally, the cytoplasmic tail domain has been shown to
be important for SV5 protein-promoted fusion, as mu-
tants lacking the cytoplasmic tail were shown to pro-
mote hemifusion but not complete fusion (Bagai and
Lamb, 1996).
One extremely important tool in the analysis of in-
fluenza virus HA-mediated fusion has been the ability
to generate the soluble ectodomain fragment, BHA, on
bromelain cleavage of virions (Brand and Skehel,
1972), as BHA has permitted biochemical and struc-
tural analyses which were not possible for a mem-
brane-bound protein (Bullough et al., 1994; Skehel et
al., 1982; Wilson et al., 1981). Production of a similar
soluble ectodomain fragment of SV5 F would ideally
involve cleavage within the short region between the
heptad repeat B and the transmembrane domain.
However, this region has been implicated to play a
role in paramyxovirus fusion, as peptides which mimic
both this region and heptad repeat B have been shown
to inhibit human parainfluenza virus type 3 (HPIV-3) F
protein-mediated fusion to a greater extent than pep-
tides having only heptad repeat B (Yao and Compans,
1996). The present study was undertaken to define the
importance of this region in SV5 F protein-promoted
membrane fusion. The results indicate that deletions
and substitutions in this region in general have little
effect on the oligomerization, transport, and fusion
functions of the F protein. However, insertions within
this region, while not significantly affecting oligomer-
ization and transport, abolish the fusion-promoting ac-
tivity. In addition, F protein mutants containing Factor
Xa sites in this region are cleaved by Factor Xa at a
very low level, suggesting that these sites are rela-
tively inaccessible to the enzyme. GPI-anchored F
protein mutants were constructed, and treatment of
the surface of cells expressing these mutants with
PI-PLC resulted in release of a much greater percent-
age of the F protein. However, these mutants were
unable to promote fusion and did not oligomerize
properly, suggesting a correlation between accessibil-
ity of this region and loss of stability and fusion-
promoting function.
MATERIALS AND METHODS
Cells and plasmid vectors
Monolayer cultures of the TC7 subclone of CV-1 cells
were grown in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal calf serum. The SV5 F
cDNA (Horvath and Lamb, 1992; Paterson et al., 1984a,b)
and the SV5 HN cDNA (Hiebert et al., 1985; Paterson et
al., 1984a) were subcloned into pGEM2X or pGEM3X,
respectively (Bagai and Lamb, 1995b, 1996). The plasmid
pGINT7 b-gal (Nussbaum et al., 1994) containing the
b-galactosidase cDNA was kindly provided by Drs. Ed-
ward Berger and Bernard Moss (National Institutes of
Health, Bethesda, MD). All cDNAs were cloned in an
orientation such that mRNA-sense RNA transcripts could
be synthesized by use of bacteriophage T7 RNA poly-
merase.
Oligonucleotide-directed mutagenesis and
construction of F protein mutants
pGEM2X-F was used as the template for mutagen-
esis of all SV5 F protein mutants except for 478SXa
and 480SXa, whose templates were pGEM2X-478IXa
and pGEM2X-480IXa, respectively. Oligonucleotide-di-
rected unique site elimination (USE) mutagenesis
(Deng and Nickoloff, 1992) was performed using the
USE mutagenesis kit following the instructions of the
supplier (Pharmacia Biotech Inc., Piscataway, NJ). Oli-
gonucleotides were synthesized by the Northwestern
University Biotechnology Facility on a DNA synthesizer
(Model ABI 380B, Perkin–Elmer, Foster City, CA). The
nucleotide sequences of the mutated regions were
determined by dideoxynucleotide chain-terminating
sequencing (Sanger et al., 1977) and analyzed by us-
ing an automated DNA sequencer (ABI Prism 310 ge-
netic analyzer, Perkin–Elmer).
For construction of F/GPI mutants, a portion of the
plasmid pDAF12 (kindly provided by Dr. Judy White, Char-
lottesville, VA) containing the gene for decay-accelerat-
ing factor (DAF) was inserted downstream of the F pro-
tein gene in pGEM2XF. USE mutagenesis was employed
to loop-out intervening regions such that the TM domain
and cytoplasmic tail coding regions of F were replaced
with either the terminal 37 amino acids of DAF (Caras et
al., 1987) (mutants F/GPI 478 and F/GPI 484) or the
terminal 28 amino acids of DAF, which together with
residue 484 of F form a minimal 29-amino-acid signal
sequence (Moran et al., 1991) (mutant F/GPI 29aa). The
nucleotide sequences of the mutated regions were con-
firmed as described above. For expression using an
SV40 recombinant virus system, the XhoI cloning site of
the late-region replacement vector pSV103 (Paterson et
al., 1985) was mutated to XbaI by insertion of linkers to
create pSV143. F/GPI mutants were subcloned into
pSV143 by addition of XbaI linkers. The pSV143-F/GPI
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DNAs were introduced into CV-1 cells together with an
SV40 early region deletion mutant helper (dl1055), and
recombinant SV40 virus stocks were prepared as de-
scribed previously (Paterson et al., 1985; Sheshberada-
ran and Lamb, 1991).
Expression of F protein mutants and metabolic
labeling of cells
The F protein mutants containing changes in the mem-
brane proximal region were expressed by use of the
recombinant vaccinia virus T7 RNA polymerase transient
expression system (Fuerst et al., 1986). Subconfluent
monolayers of CV-1 cells were infected with recombinant
vaccinia virus vTF7-3 at approximately 10 pfu per cell and
incubated at 37°C for 30 min. The virus inoculum was
then removed and cells were transfected with wt or
mutant plasmid DNA using cationic liposomes prepared
as described previously (Rose et al., 1991). Typically 2.5
mg of plasmid DNA in 1.0 ml of OPTI-MEM (GIBCO-BRL,
Gaithersburg, MD) was used for a 35-mm tissue culture
dish and 5.0 mg of plasmid DNA in 2.0 ml of OPTI-MEM
was used for a 60-mm tissue culture dish. At 5 h post-
transfection (p.t.), cells were washed twice in phosphate-
buffered saline (PBS) and incubated in cysteine- and
methionine-deficient DMEM (DMEM Cys2Met2) for 30
min. For pulse-chase experiments, cells were labeled
with Tran[35S]-label (100 mCi/ml) (ICN Radiochemicals,
Irvine, CA) in DMEM Cys2Met2 for the pulse period
indicated. The chase period was initiated by removal of
the labeling medium, the cells were washed with pre-
warmed chase medium (DMEM supplemented with 2
mM unlabeled cysteine and methionine), and additional
chase medium was added. The cells were incubated at
37°C for varying periods after which they were lysed in
ice-cold RIPA buffer containing protease inhibitors
(Paterson and Lamb, 1987) and 25 mM iodoacetamide.
The F/GPI mutant proteins were expressed by use of
either the recombinant vaccinia T7 transfection system,
as described above, or infection of CV-1 cells with
SV40-F or F/GPI recombinant virus. For SV40 recombi-
nant virus experiments, subconfluent monolayers of CV-1
cells were infected with recombinant SV40 stocks for 1 h
at 37°C. Virus was removed, and cells were incubated in
DMEM containing 2.5% NUserum (GIBCO-BRL) for 40–44
h prior to initiation of starvation, labeling, and chase
periods.
Chemical crosslinking of mutant F proteins
CV-1 cells expressing the SV5 wt or mutant F proteins
were labeled with Tran[35S]-label (100 mCi/ml) in DMEM
Cys2Met2 for 30 min at 5 h p.t. and incubated in chase
medium for 2 h. Chemical crosslinking analysis was
performed as described previously (Russell et al., 1994)
using the crosslinking reagent 3,39-dithiobis (sulfosuc-
cinimidyl propionate) (DTSSP) (Pierce Chemical Co.,
Rockford, IL).
Immunoprecipitation, SDS–PAGE, and quantification of
autoradiograms
Wt and mutant F proteins were immunoprecipitated
from cell lysates with a rabbit antiserum raised against a
mixture of three synthetic peptides specific for F2 resi-
dues 22 to 39, 31 to 46, and 77 to 94 (Horvath and Lamb,
1992). Immunoprecipitation was performed as described
previously (Lamb et al., 1978). Crosslinked polypeptides
were analyzed on 3.5% acrylamide gels (Gething et al.,
1989; Russell et al., 1994). Nonreduced F polypeptides
were analyzed on 10% acrylamide gels and reduced F
polypeptides on 15% acrylamide gels. Gels were dried at
80°C for 2 h and exposed to phosphoimager screens
and radioactivity was quantified by a phosphoimager
(FUJI Medical Systems USA Inc., Stamford, CT). Alterna-
tively, gels were processed for fluorography as described
previously (Lamb and Choppin, 1976; Paterson and
Lamb, 1993).
Endo-b-N-acetylglucosaminidase digestions
To test for the conversion of N-linked carbohydrate
chains from high mannose to the complex form, immune
complexes were digested with 1 mU of endo-b-N-acetyl-
glucosaminidase (Endo H) (Boehringer-Mannheim Bio-
chemicals, Indianapolis, IN) as described previously (Ng
et al., 1989).
Deoxymannojirimycin treatment
To test for the presence of complex carbohydrates,
proteins were expressed as previously described, except
that 0.5 mM 1-deoxymannojirimycin (Calbiochem, La
Jolla, CA) was included in the media during the starva-
tion, labeling, and chase periods.
Flow cytometry
CV-1 cells were transfected with wt or mutant F protein
plasmids as previously described. At 5 h p.t. cells were
washed twice and incubated at 33°C overnight in DMEM
containing 2.5% fetal calf serum. The cells were then
chilled on ice and treated for flow cytometric analysis as
described previously (Horvath and Lamb, 1992) using
monoclonal antibody F1a specific to the SV5 F glycopro-
tein (Randall et al., 1987) as the primary antibody and
fluorescein isothiocyanate-conjugated goat anti-mouse
IgG as the secondary antibody. Fluorescence intensity of
10,000 cells was measured by using a FACSCalibur flow
cytometer (Becton–Dickinson, Mountain View, CA).
Membrane lipid mixing assay: Confocal microscopy
Fresh human erythrocytes (RBCs) were labeled with
the lipid probe octadecyl rhodamine B (R18) (Molecular
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Probes, Eugene, OR) as described previously (Bagai and
Lamb, 1995b; Morris et al., 1989). The microscopy assay
for lipid mixing was carried out as described previously
(Bagai and Lamb, 1996), and the extent of fusion was
visualized and photographed by using a confocal micro-
scope system (Zeiss LSM 410, Carl Zeiss, Inc., Thorn-
wood, NY).
Content mixing assay
The assay for fusion content mixing is based on the
cytoplasmic activation of the reporter gene b-galac-
tosidase and was carried out essentially as described
previously (Bagai and Lamb, 1995b, 1996; Nussbaum
et al., 1994). Cell fusion was measured by the colorimet-
ric lysate assay for b-galactosidase as described previ-
ously (Nussbaum et al., 1994), and the results were read
by a plate reader (ELX800, Bio-tek Instruments, Inc.,
Winooski, VT).
Factor Xa cleavage assay
CV-1 cells expressing the wt F and mutant F proteins
were metabolically labeled with Tran[35S]-label (100 mCi/
ml) at 5 h p.t. for 2 h and incubated in DMEM 1 1% BSA
containing Factor Xa (2.5 mg/ml) for 3 h. Polypeptides in
the supernatant and in the cell lysate (made to an equal
volume as the supernatant) were immunoprecipitated
with F2-specific antiserum and analyzed by SDS–PAGE
on 15% gels in the presence of reducing agent.
Phosphatidylinositol phospholipase C (PI-PLC)
cleavage assay
CV-1 cells infected with SV40-F or F/GPI recombinant
virus were metabolically labeled with Tran[35S]-label (100
mCi/ml) at 42–44 h p.i. for 3 h, washed two times with
PBS, and incubated for 1 h in PBS, 0.1% BSA containing
100 to 500 mU/ml PI-PLC (Molecular Probes). Compari-
son of polypeptides in the supernatant and cell lysates
was carried out as described above for Factor Xa
cleavage.
RESULTS
Construction of the mutants and expression
in CV-1 cells
To investigate the role of the seven residues that lie
between the SV5 F protein heptad repeat B region (res-
idues 453 to 477) and the presumptive boundary of the
TM domain (residue 485), and to determine if it was
possible to create a site in this region that could be
cleaved by protease, a series of specific mutations were
made (Fig. 1). Two insertion mutants, 478IXa and 484IXa,
were made in which four residues encoding the Factor
Xa recognition site (IEGR) were inserted into the region
after residues 478 and 484, respectively. Two substitution
mutants, 478SXa and 480SXa, were made in which the
four residues after 478 or 480 were substituted to resi-
dues IEGR. Another three insertion mutants, 484 1 2,
484 1 4, and 484 1 6, were made by addition of two, four,
or six amino acids after residue 484, choosing residues
that duplicated those already found in this region. Finally,
four deletion mutants, 484D2, 484D4, 484D6, and 484D8,
were constructed in which the two, four, six, or eight
residues prior to amino acid 484 were deleted.
The 11 mutants were expressed in CV-1 cells using the
recombinant vaccinia virus T7 RNA polymerase system.
The cells were metabolically labeled with Tran[35S]-label
for 15 min and incubated in chase medium for 0 or 3 h.
Cells were lysed, proteins were immunoprecipitated us-
ing an F2 polyclonal antiserum, and polypeptides were
analyzed by SDS–PAGE (Fig. 2). All the mutant proteins
were expressed in CV-1 cells at levels comparable to the
wt F protein, and all the mutant F proteins were cleaved
into the disulfide-linked subunits, F1 and F2, after a 3-h
chase period with the exception of mutant 484D6, which
only showed low levels of cleavage. Mutant 478SXa
polypeptide species were found to migrate heteroge-
neously after 0- or 3-h chase periods, most likely the
result of heterogeneous carbohydrate modifications to
the protein. However, quantification of the F2 band was
unaffected by the modifications, indicating that this mu-
tant is expressed at a level similar to the wt F protein.
Oligomerization of the mutants
It has been previously shown that the SV5 F protein
forms a homooligomer (most likely a homotrimer) shortly
after its synthesis in the endoplasmic reticulum (Russell
et al., 1994). To examine for oligomerization of the mutant
F proteins, chemical crosslinking was performed on all
mutant F proteins. It was found that all the mutant F
proteins were crosslinked to homooligomers (species 3,
Fig. 3). Examples of the data obtained for F mutants
478IXa, 484IXa, 484D6, and 484D8 are shown in Fig. 3.
Crosslinking was found to be much more efficient in the
presence of NP-40, as described previously (Russell et
al., 1994). As all of the F mutant proteins could form
homooligomers similar to those found for wt F protein
(see Fig. 8C for wt F protein data), these data suggest
that the mutations made do not significantly disrupt oli-
gomerization.
Analysis of the rate of intracellular transport and
surface expression of the mutant F proteins
To examine the intracellular transport of the mutant F
proteins to the medial-Golgi apparatus, the rate of acqui-
sition of carbohydrate chains resistant to Endo H diges-
tion was determined. It has been shown previously that
the two carbohydrate chains on the F2 subunit remain in
the high mannose form and do not acquire resistance to
Endo H digestion (Bagai and Lamb, 1995a; Horvath and
Lamb, 1992), whereas most of the carbohydrate chains
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on the F1 subunit acquire Endo H resistance. Quantifi-
cation of Endo H resistance kinetics for all the mutant F
proteins is shown in Fig. 4. The wt F protein acquired
Endo H resistance with a t1/2 of ;80 min; by 180 min
when the kinetic curve had reached a plateau, 75% of the
F protein was Endo H resistant. All mutant F proteins
gained Endo H resistance at a rate similar to that seen
with the wt F protein with the exception of mutant 484D6.
For this mutant, less than 30% of the molecules acquired
Endo H resistance by 180 min, suggesting that its rate of
intracellular transport was considerably slowed in com-
parison to the other mutant F proteins. The precursor
molecule F0 is cleaved to the disulfide-linked subunits F1
and F2 in the trans-Golgi network (Klenk and Garten,
1994; Morrison et al., 1985) and time-course analysis of
the rate of cleavage of F0 to F1 and F2 indicated that only
mutant 484D6 showed significantly different intracellular
transport kinetics from the wt F protein (data not shown).
The cell surface expression of the mutant F proteins
was quantified by flow cytometry using an F-specific
monoclonal antibody, F1a, and an FITC-conjugated goat
anti-mouse secondary antibody. The mean fluorescence
intensities (MFI) were normalized to that of the wt F
protein. All mutants except one showed approximately
the same MFI as the wt F protein (Table 1) with the
exception again being mutant 484D6, which had a lower
MFI (0.72) than the wt F protein (1.0).
Fusion activity of the mutant F proteins
Cell fusion involves both fusion of the outer leaflet,
causing lipid mixing, and fusion of the inner leaflet,
FIG. 1. Schematic diagram of the SV5 F protein and the mutant F proteins. 478IXa, 484IXa, 478Sxa, and 480SXa are insertion (I) or substitution (S)
mutants of the F protein in which the Factor Xa protease recognition site, IEGR, was inserted or substituted into the region between the heptad repeat
B and the putative boundary of the transmembrane domain. Varying numbers of residues were inserted into the same region in the three ‘‘addition’’
mutants: 484 1 2, 484 1 4, and 484 1 6. Four deletion mutants contained deletions in the same region: 484D2, 484D4, 484D6, and 484D8. The positions
of the fusion peptide (FP), heptad repeat A (HRA), heptad repeat B (HRB), and the putative ectodomain boundary of the TM domain are indicated.
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leading to complete fusion and mixing of the cytoplasmic
contents. A quantitative reporter gene activation assay
was employed to measure content mixing (Fig. 5). Three
of the four deletion mutants (484D2, 484D4, and 484D8)
had approximately the same fusion activity as the wt F
protein. Again, the exception was mutant 484D6, which
showed no content mixing above background levels,
demonstrating that for this mutant, both intracellular
transport and fusion promotion functions were impaired.
The two substitution mutants (478SXa and 480SXa) gave
rise to approximately 60 or 70%, respectively, of the
content mixing observed with wt F protein. However, four
of the five mutants containing insertions in the spacer
region (478IXa, 484IXa, 484 1 4, and 484 1 6) showed no
significant content mixing, and the remaining mutant,
484 1 2, promoted content mixing that was only 25% of
the level observed with wt F protein, suggesting that
addition of amino acids to this region results in highly
reduced or abolished fusion promotion activity. The con-
tent mixing results of the reporter gene activation assay
were confirmed by a syncytium formation assay (data not
shown).
A mutant of the SV5 F protein lacking its cytoplasmic
tail region has been demonstrated to promote hemi-
fusion, but not complete fusion (Bagai and Lamb,
1996). To examine the lipid-mixing ability of the mutant
F proteins, red blood cells (RBCs) prelabeled with the
fluorescent lipid probe R18 were incubated with CV-1
cells expressing SV5 HN and the wt F or mutant F
proteins. After removal of excess RBCs, the cells
bound with RBCs were shifted to 37°C for 10 min after
which transfer of the lipid dye was examined using a
confocal microscope. Examples of both positive and
negative data are shown in Fig. 6. The two insertion
mutants (478IXa and 484IXa) and the three addition
mutants (484 1 2, 484 1 4, and 484 1 6) did not show
R18 transfer from the bound RBCs to the CV-1 cells,
indicating that these mutants were unable to cause
hemifusion during the 10-min time period of the assay.
Both of the substitution mutants (478SXa and 480SXa)
and three of the four deletion mutants (484D2, 484D4,
and 484D8) showed R18 transfer indistinguishable
from the wt F protein. However, no detectable lipid-
FIG. 2. Expression of mutant F proteins. CV-1 cells were infected with vaccinia virus vTF7-3 at 10 pfu per cell for 30 min at 37°C and then transfected
with plasmids encoding the wt F or mutant F proteins as described under Materials and Methods. Transfected cells were metabolically labeled with
Tran[35 S]-label (100 mCi/ml) at 5 h p.t. for 30 min and incubated in chase medium for 0 or 3 h. Polypeptides were immunoprecipitated with F2-specific
polyclonal antiserum and analyzed by SDS–PAGE on 15% gels in the presence of reducing agent. The positions of the uncleaved F0 and the cleaved
subunits F1 and F2 are indicated. Note that the band near the F1 position at 0 h is a vaccinia virus polypeptide that co-precipitates. Mock represents
polypeptides immunoprecipitated from uninfected cells.
FIG. 3. Oligomerization of the mutant F proteins. CV-1 cells express-
ing the mutant F proteins were metabolically labeled with Tran[35S]-
label (100 mCi/ml) at 5 h p.t. for 30 min and incubated in chase medium
for 2 h at 37°C. Crosslinking reactions were performed on cell suspen-
sions in the absence (2) or presence (1) of 0.5% detergent NP-40 and
the crosslinking reagent DTSSP as described under Materials and
Methods. F protein species were immunoprecipitated and analyzed on
a 3.5% gel in the absence of reducing agent. The three predominant
oligomeric species are indicated by arrowheads.
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mixing activity was detected with mutant 484D6. Thus,
the lipid-mixing data and the content mixing data for
the mutant F proteins are concordant and indicate that
insertion of residues into the membrane proximal re-
gion is deleterious for biological activity but that de-
letion or substitution of residues can be tolerated
without grossly affecting biological activity. The slight
discrepancy to the concordance of the data for lipid
mixing and content mixing was for F mutant 484 1 2,
where ;25% (compared to wt F protein) content mix-
FIG. 4. Kinetics of intracellular transport of mutant F proteins to the medial Golgi apparatus. CV-1 cells expressing the wt F or mutant F proteins
were metabolically labeled with Tran[35S]-label (100 mCi/ml) at 5 h p.t. for 15 min and incubated in chase medium for the times indicated at 37°C.
Polypeptides were immunoprecipitated with F2-specific antiserum and treated (1) or not treated (2) with endo-b-N-acetyl-glucosaminidase H (Endo
H) and analyzed by SDS–PAGE on 10% gels in the absence of reducing agent. Quantification of radioactivity was determined as described under
Materials and Methods.
TABLE 1
Surface Expression of F Proteins
Protein
Relative number
of positive cellsa
Mean fluorescence
intensityb
wt F 1 1
478IXa 0.82 0.99
484IXa 0.89 0.99
478SXa 1.04 1.09
480SXa 1.05 1.08
484 1 2 0.96 0.99
484 1 4 0.97 1.08
484 1 6 1.02 1.01
484D2 1.01 0.95
484D4 1.01 1.11
484D6 1.04 0.72
484D8 1.05 0.99
a Determined from flow cytometry data and normalized to wt F. Wt F
protein raw data were about 50% positive cells.
b Determined from flow cytometry data and normalized to wt F.
FIG. 5. Reporter gene activation membrane fusion assay for the wt F
and mutant F proteins. One culture of CV-1 cells was infected with
recombinant vaccinia virus vTF7-3, which encodes T7 RNA polymer-
ase, and cotransfected with plasmid DNA encoding the cDNAs for the
SV5 HN and wt F or mutant F proteins. A second culture of CV-1 cells
was infected with wt vaccinia virus and transfected with plasmid
pGINT7b-gal which encodes b-galactosidase. The cell populations
were suspended in OPTI-MEM containing 2.5 mM CaCl2 at 10
6 per
milliliter. Mixtures of the two populations of cells (0.1 ml each) were
plated in triplicate in 96-well plates and incubated at 37°C for 4 h.
Samples were analyzed by the colorimetric lysate assay and the O.D.
was read by a plate-reader. Each column represents an average of
three independent experiments each performed in triplicate (6SD). The
data were normalized to represent the fusion observed with wt F
protein as 100%.
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ing was observed, but no lipid mixing. This may be
explained by the fact that the duration of the lipid
mixing assay was only 10 min compared to the 4-h
duration of the content mixing assay.
Cleavage of the mutant F proteins containing a Factor
Xa cleavage site by Factor Xa
To determine whether mutants containing a Factor Xa
cleavage site could be used to generate soluble SV5 F
protein, CV-1 cells expressing either wt F or mutant F
proteins containing Factor Xa cleavage sites were met-
abolically labeled with Tran[35S]-label for 3 h and then
incubated with Factor Xa (2.5 mg/ml). The supernatant
and the cell lysate were immunoprecipitated and
polypeptides analyzed by SDS–PAGE. As shown in Fig. 7,
a fraction of the ectodomain of mutants 478IXa, 484IXa,
and 478SXa was released into the supernatant by Factor
Xa treatment. As expected, the F1 band in the superna-
tant had a faster mobility than the F1 band in the cell
lysate, as the TM domain and the cytoplasmic tail were
removed by cleavage with Factor Xa. Detectable F1 and
F2 bands were not seen in the supernatant from 480SXa,
suggesting that the Xa site in this mutant is inaccessible
to Factor Xa. Quantification of the F1 bands showed that
less than 1% of the total protein of mutants 478IXa,
484IXa, and 478SXa was cleaved by Factor Xa. Other
digestion conditions, including higher concentrations of
Factor Xa and longer incubation times, were tested, but
FIG. 6. Lipid mixing assay for the cells expressing wt F protein and mutant F proteins 478IXa and 480SXa. Human red blood cells labeled with R18
were bound to CV-1 cells coexpressing SV5 HN and either wt F or mutant F proteins. Membrane fusion between RBCs and the F-expressing cells
was triggered by incubation at 37°C for 10 min. The distribution of R18 dye was visualized by confocal microscopy.
FIG. 7. Factor Xa cleavage of mutant F proteins containing Xa sites.
CV-1 cells expressing the wt F and mutant F proteins were metaboli-
cally labeled with Tran[35S]-label (100 mCi/ml) at 5 h p.t. for 2 h and
incubated in DMEM/1% BSA containing Factor Xa (2.5 mg/ml) for 3 h.
The supernatant was harvested and cells were lysed in an equivalent
volume of lysis buffer. Polypeptides were immunoprecipitated with
F2-specific antiserum and analyzed by SDS–PAGE on a 15% gel in the
presence of reducing agent. A 1 day exposure to a phosphoimager
screen was used for the polypeptides in the cell lysates, and a 3 day
exposure was used for the proteins in the supernatant fraction.
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the percentage of mutant F proteins cleaved by Factor Xa
was not significantly increased (data not shown).
Construction of F/GPI mutants and surface
expression in CV-1 cells
Several membrane-bound proteins have been geneti-
cally engineered to contain a GPI anchor that can be
cleaved with PI-PLC to release a soluble ectodomain
fragment. To construct a GPI-linked SV5 F protein, se-
quences from the C-terminal region of DAF were joined
to the ectodomain of SV5 F protein (Fig. 8A). As the
precise boundary of the TM domain is not known, the
37-amino-acid GPI addition sequence from DAF (Caras
et al., 1987) was placed after either threonine 478 (F/GPI
478) or serine 484 (F/GPI 484). Furthermore, as addition
of other amino acids to this region resulted in loss of
fusion function (see above), a GPI mutant was con-
structed which added the terminal 28 amino acids of DAF
after residue 484 (F/GPI 29aa), resulting in a molecule
containing a minimal 29-amino-acid GPI addition signal
FIG. 8. Expression and oligomerization of F/GPI mutant proteins. (A). Three chimeric proteins were constructed in which the TM domain and
cytoplasmic tail of SV5 F protein were replaced with a segment of DAF encoding a GPI addition signal. The beginning of the residues added from
DAF are shown in hatched boxes, with the complete addition being PNKGSGTTSGTTRLLSGHTCFTLTGLLGTLVTMGLLT for F/GPI 484 and 478, and
GTTRLLSGHTCFTLTGLLGTLVTMGLLT for F/GPI 29aa. The point at which cleavage and addition of the GPI anchor is predicted to occur is indicated
by an arrowhead. (B). CV-1 cells were infected with SV40–F/GPI recombinant viruses for 1 h at 37°C. At 42 h p.i. cells were metabolically labeled with
Tran[35S]-label (100 mCi/ml) for 30 min, and then incubated in chase medium for 0 or 3 h. Deoxymannojirimycin (0.5 mM), where indicated (1), was
included for 30 min prior to the pulse-label and in all subsequent media. The positions of the uncleaved F0 and cleaved F1 and F2 subunits are
indicated. F1 hg, hyperglycosylated F1 species. (C). CV-1 cells were infected with SV40-F/GPI recombinant viruses and metabolically labeled as in B
and incubated in chase medium for 3 h. Chemical cross-linking with DTSSP with (1) or without (2) 0.5% NP-40 was performed as described under
Materials and Methods and polypeptides were analyzed on a 3.5% non-reducing gel.
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(Moran et al., 1991). Addition of the GPI anchor to F/GPI
29aa should result in a final molecule that does not
contain residues derived from DAF.
The three F/GPI mutants were expressed in CV-1
cells using either the recombinant SV40 virus system
or the recombinant vaccinia virus T7 RNA polymerase
system. Mutants F/GPI 478 and F/GPI 29aa were ex-
pressed at the cell surface, as judged by indirect
immunofluorescence; quantification by flow cytometric
analysis of F/GPI 478 and F/GPI 29aa expressed using
the vac-T7 expression system indicated mean fluores-
cent intensities of 20.3 and 20.4% of wt F protein,
respectively. No significant surface fluorescence was
detected for mutant F/GPI 484 (data not shown) when
the protein was expressed by using either expression
system, suggesting that addition of this GPI anchor,
which was accompanied by insertion of several amino
acids to the membrane proximal region, resulted in
impaired intracellular transport. Thus, properties of
F/GPI 484 were not pursued further.
Oligomerization, cleavage, and fusion activity of F/GPI
mutants
To examine the properties of oligomerization, cleav-
age, and biological activity of the F/GPI mutants, SV40
recombinant-virus-infected cells expressing wt F pro-
tein, F/GPI 478 or F/GPI 29aa, at 42 h p.i., were met-
abolically labeled with Tran[35S]-label for 30 min and
incubated in chase medium for 0 or 3 h. Cells were
lysed, proteins immunoprecipitated, and polypeptides
analyzed by SDS–PAGE. As shown in Fig. 8B, even
though F/GPI 478 and F/GPI 29aa were expressed at
levels comparable to wt F protein, only a small per-
centage of these F/GPI mutant proteins was cleaved
after a 3-h chase period, as judged by the appearance
of the F2 species. For both F/GPI mutants, a population
of the F1 species (F1 hg) had slower gel mobilities than
normal, but these hyperglycosylated species could be
returned to their expected mobilities by addition of the
inhibitor of mannosidase I, deoxymannojirimycin (Fig.
8B), suggesting that the F1 subunit of F/GPI 478 and
F/GPI 29aa contained different complex carbohydrate
modifications from wt F protein.
The ability of the F/GPI mutants to form oligomers
when expressed using the SV40 recombinant-virus sys-
tem was examined by using the bifunctional crosslinking
reagent DTSSP. Although a reduction in the monomeric
species 1 was observed for F/GPI 478 and F/GPI 29aa
mutants on addition of DTSSP, no discrete crosslinked
species corresponding to species 3 were found in either
the presence or absence of NP-40 (Fig. 8C). However, in
the presence of crosslinker an increase in background
radioactivity was observed throughout the gel lane, pos-
sibly due to the formation of aggregates of heteroge-
neous sizes. Similar data for crosslinking were obtained
when the F/GPI mutants were expressed using the re-
combinant vaccinia T7 RNA polymerase system (data not
shown).
The fusion properties of F/GPI478 and F/GPI 29aa
expressed using the vaccinia T7 system were examined
by use of both the R18 lipid-mixing assay and the b-
galactosidase cytoplasmic content mixing assay. Neither
F/GPI 478 nor F/GPI 29aa was capable of promoting lipid
mixing or content mixing.
Production of soluble F protein by treatment
with PI-PLC
To determine whether a soluble F ectodomain could
be generated by cleavage of the GPI anchor, cells ex-
pressing metabolically labeled wt F, F/GPI 478, or F/GPI
29aa mutant proteins (using the SV40-recombinant virus
system) were treated with PI-PLC. Polypeptide species
corresponding to F0, the heterogeneously glycosylated
F1, and a species corresponding to F2 were detected in
the supernatant from cells expressing F/GPI 29aa and
F/GPI 478 mutant proteins but very little for wt F protein
(Fig. 9), indicating that F/GPI 29aa and F/GPI 478 mutant
proteins contained a GPI anchor which was at least
partially accessible to PI-PLC. It should be noted that
hyperglycosylated F1 migrates with a mobility greater
than that of F0 (see Fig. 8B). A change in mobility on
cleavage, analogous to that seen for Factor Xa-cleaved F
protein, was not readily discernible for the F GPI mutants
as the hyperglycosylated form is considerably larger
than the wt F1 species. To quantify the amount of protein
released, cell surface proteins were biotinylated prior to
treatment with PI-PLC, and the biotinylated protein pop-
ulations of both cell and supernatant fractions were sep-
arated from unbiotinylated proteins by streptavidin–
agarose bead affinity purification prior to immunoprecipi-
tation with the F-specific polyclonal sera. Approximately
25% of the biotinylated population was found in the
supernatants, indicating that one-quarter of the cell sur-
face F/GPI 29aa and F/GPI478 molecules were cleaved
by PI-PLC under these conditions (data not shown). Less
than 1% of the wt F protein appeared in the supernatant
fractions, and this was most likely due to contamination
of the supernatant with the cellular fraction (data not
shown).
DISCUSSION
For several paramyxovirus F proteins it has been
found that peptides that mimic the C-terminal heptad
repeat B inhibit fusion (Lambert et al., 1996; Rapaport et
al., 1995; Yao and Compans, 1996). In the case of the
paramyxovirus HPIV-3, peptides containing the residues
of heptad repeat B and the adjacent region up to the
boundary of the presumptive TM domain exhibited a
greater degree of inhibition of fusion (Yao and Compans,
1996). These observations suggest that the small region
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between the presumptive ectodomain boundary with the
TM domain and heptad repeat B plays a role in fusion.
Here, we provide direct evidence to support this hypoth-
esis. While substitutions and deletions could, with only
one exception, be tolerated without loss of proper F
protein oligomerization or fusogenic activity, insertion of
the selected residues into this region resulted in mutant
F proteins that, although able to undergo oligomerization
and transport, were unable to promote either hemifusion
or complete fusion. The lack of fusion activity with the
insertion mutants is not due to a general instability of the
mutants, as these insertion mutants were indistinguish-
able from wt F protein in terms of their oligomerization
and rates of intracellular transport. It has been hypothe-
sized that the SV5 F protein undergoes a conformational
change to initiate membrane fusion, perhaps analogous
to the low-pH-induced conformational change of the in-
fluenza HA (reviewed in Lamb, 1993). It is possible that
insertions in the membrane proximal region block such a
conformational change and thereby prevent fusion. It has
been shown for HIV gp120/gp41 that interactions be-
tween the two gp41 heptad repeats are a fundamental
component of the putative fusogenic structure (Chan et
al., 1997; Weissenhorn et al., 1997) and insertion next to
the heptad repeat B of the SV5 F protein may prevent an
analogous interaction. Alternatively, the amphipathic na-
ture of the heptad repeat B a-helix may allow interaction
with a lipid bilayer during fusion that is blocked by
insertions that increase the distance between the two.
Finally, insertions in this region may impair interactions
between F protein homotrimers which, by analogy to
influenza HA, may be required to form a fusion pore
(Danieli et al., 1996).
It would appear that there is not an absolute spacing
requirement between the presumptive boundary of the
TM domain and heptad repeat B, as deletions within the
region were in general tolerated with no measurable
effect on structure or function. The exception was mutant
484D6, which had slower intracellular transport kinetics,
was present at the surface in reduced amounts com-
pared to the wt F protein, and was unable to promote
fusion. It does not appear that the reason for the altered
properties of the mutant was simply the removal of too
many residues from this region, as F mutant 484D8, in
which the entire region between the putative TM and
heptad repeat B has been removed, retained oligomer-
ization properties, intracellular transport kinetics, and
fusogenic activity similar to the wt F protein. As both
heptad repeat B and the TM domain are proposed to
form a-helices, it seems reasonable that these domains
must be in a proper orientation for protein function. It is
possible that with 484D8, in which all residues between
heptad repeat B and the TM domain have been removed,
the a-helices are in the appropriate orientation for pro-
tein function, but that with 484D6 one of the a-helices
shifts such that it is improperly oriented.
It would also appear that conservation of sequence of
the region between the presumptive boundary of the TM
domain and heptad repeat B is not required for F protein
structure and biological activity. Two mutants in which
amino acids starting at either 478 or 480 were substi-
tuted with the Factor Xa cleavage site IEGR retained
fusogenic activity. Mutant 478SXa demonstrated a com-
plex mobility pattern on polyacrylamide gels, which
could be partially abolished by incubation with the inhib-
itor of mannosidase I, deoxymannojirimycin, data which
suggest that the complex gel migration pattern is due in
part to additional carbohydrate modification.
Treatment of cells expressing mutant F molecules
containing Factor Xa cleavage sites with Factor Xa failed
to release more than 1–2% of the total protein. For F
protein mutant 484SXa, which was indistinguishable
from wt F protein in terms of biological activity, no evi-
dence could be obtained for the release of the ectodo-
main. Thus, these data suggest that the Factor Xa cleav-
age site is largely or completely inaccessible to the
enzyme.
Replacement of the normal protein anchor with a GPI
FIG. 9. PI-PLC cleavage of F/GPI mutants. CV-1 cells were infected
with SV40–F/GPI recombinant viruses (F/GPI 478 and F/GPI 29aa) for
1 h at 37°C. At 42 h p.i. cultures were metabolically labeled with
Tran[35S]-label (100 mCi/ml) for 30 min and incubated in chase medium
for 3 h. Cultures were then incubated for 1 h with PBS, 0.1% BSA
containing 500 mU/ml PI-PLC. Cell and supernatant fractions were
processed as described in the legend to Fig. 7. Radioactivity was
detected by fluorography. The gel of the proteins derived from the cell
lysate was exposed for 3 days, while the gel containing the polypep-
tides in the supernatant was exposed for 2 weeks. F1 hg, hyperglyco-
sylated F1 species.
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linkage has been accomplished for a number of viral
membrane proteins, including the VSV G protein (Crise et
al., 1989), the influenza HA protein (Kemble et al., 1993),
the Rous sarcoma virus envelope glycoprotein (Gilbert et
al., 1993), and the HIV type 1 envelope glycoprotein
(Salzwedel et al., 1993), allowing for both release of a
soluble ectodomain fragment and examination of the role
of the transmembrane domain of these proteins in fusion.
Addition of the commonly used 37-amino-acid GPI addi-
tion sequence from DAF after residue 484 of SV5 F
protein (F/GPI 484) resulted in a mutant F protein which
was unable to reach the cell surface. However, addition
of the 37-amino-acid DAF sequence after residue 478 of
the SV5 F protein (F/GPI 478), or addition of the terminal
28 amino acids from DAF after residue 484 of SV5 F
protein, to create a minimal 29-amino-acid GPI addition
sequence (F/GPI 29aa), resulted in F/GPI proteins which
were present on the surface at 20% of the level seen with
wt F protein. For these mutants, the number of amino
acids between the GPI anchor and the heptad repeat B
was either identical to that found between the TM do-
main and heptad repeat B of the wt F protein (F/GPI
29aa) or involved addition of only three residues (F/GPI
478), whereas mutant F/GPI 484 which was not trans-
ported to the cell surface contained an additional nine
residues. These data indicate that the distance between
the membrane and heptad repeat B can play a role in
protein stability when the TM domain of the protein has
been replaced by a GPI anchor.
The available data indicate that the GPI anchor was
added to the mutants F/GPI 478 and F/GPI 29aa, as
cleavage with PI-PLC released the F ectodomain. Ap-
proximately 25% of the cell surface population could be
cleaved by PI-PLC under the conditions tested. It is
unknown whether the percentage that was uncleaved is
due to inaccessibility of the region to the enzyme or to
modifications that render the GPI anchor resistant to
cleavage by PI-PLC (Walter et al., 1990). Nonetheless,
addition of a GPI anchor is a more effective means of
generating the SV5 F protein ectodomain than introduc-
tion of Factor Xa cleavage sites into the membrane
proximal region. However, the lack of both proper trim-
erization and fusogenic activity of the F/GPI mutants
effectively precludes their use in further structural stud-
ies. Taken together, the data from both the Factor Xa
mutants and the F/GPI mutants suggest that there is a
correlation between accessibility of the membrane prox-
imal region of the SV5 F protein and loss of oligomeriza-
tion and fusogenic activity.
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